RLYB

Insider Trades

Name	Value	Action	Price	Current Price
ADAR1 Capital Management, LLC10 Percent Owner $2.8k200 shares BuyMay 19, 2026 $13.80 --
ADAR1 Capital Management, LLC10 Percent Owner $140k10k shares BuyMay 19, 2026 $13.98 --
ADAR1 Capital Management, LLC10 Percent Owner $84k6k shares BuyMay 18, 2026 $13.98 --
ADAR1 Capital Management, LLC10 Percent Owner $2.8k200 shares BuyMay 15, 2026 $13.95 --
ADAR1 Capital Management, LLC10 Percent Owner $1.4k100 shares BuyMay 15, 2026 $13.80 --
ADAR1 Capital Management, LLC10 Percent Owner $1.1M75.2k shares BuyMay 13, 2026 $14.00 --

News

gurufocus.comAre SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?gurufocus.comJun 9

prnewswire.comAre SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?prnewswire.comJun 9

gurufocus.comRallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYBgurufocus.comJun 2

businesswire.comRallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYBbusinesswire.comJun 2

prnewswire.comShareholder Alert: Ademi LLP investigates whether Rallybio Corporation is obtaining a Fair Price for Public Shareholdersprnewswire.comJun 2

Trade RLYB

About Rallybio Corporation

Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.

CEO: Stephen Uden
IPO Date: Jul 29, 2021

Market Data

Open: $15.79
High: $16.23
Low: $15.79
Volume: 23.6K
Avg Volume: 253.7K
52W High: $17.57
52W Low: $2.40

Valuation

Market Cap: $93M
Enterprise Value: $51M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-30M
Revenue: $858k
Net Income: $-9.0M
Cash: $31M
Debt: $176k

Events

EarningsAug 6

EPS est. -1.28